DTIL 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

DTIL ▼ -15.17% at T+20d

NEUTRAL call ✗ call lost -15.17% · α vs SPY -20.12% · entry $7.45 → $6.32

Next anchor: T+60d in 6w

Last close $6.10 (close Jun 12) · -18.12% from $7.45 entry

Entry anchored
May 5, 2026
via day open

T+1d

+0.94%

call +0.94% · α -0.45%

$7.52

settled 6w ago

T+5d

+10.07%

call +10.07% · α +8.08%

$8.20

settled 5w ago

T+20d

-15.17%

call -15.17% · α -20.12%

$6.32

settled 12d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Precision BioSciences reported Q1 2026 revenue of $10.8M (up from ~$0.1M YoY) and a net loss of $(0.75)/share, narrowing from $(2.21)/share in Q1 2025. The quarter was driven by milestone revenue from TG Therapeutics and a legacy collaboration, while clinical execution advanced for PBGENE-HBV (16 patients dosed, late-breaker at EASL) and PBGENE-DMD (first site activated, enrolling patients). Cash of $125.8M is expected to fund both programs through 2028.

Actionable Insight

The stock will trade on upcoming clinical catalysts: PBGENE-HBV late-breaker data at EASL (May 27-30) and PBGENE-DMD enrollment updates. Cash runway through 2028 removes near-term financing overhang. Monitor for any safety signals or efficacy readouts from the EASL poster.

Key Facts

Q1 2026 revenue $10.8M vs ~$0.1M in Q1 2025, driven by TG Therapeutics milestone and legacy collaboration
Net loss narrowed to $(18.4M) or $(0.75)/share from $(20.6M) or $(2.21)/share YoY
Cash, cash equivalents, and restricted cash of $125.8M as of March 31, 2026
PBGENE-HBV: 16 patients dosed across 5 cohorts; late-breaking poster accepted at EASL Congress May 27-30
PBGENE-DMD: First clinical site (Arkansas Children's Hospital) activated and enrolling patients in FUNCTION-DMD trial
TG Therapeutics milestone payment of $7.5M received in April 2026 ($5.25M cash + $2.25M stock)
Cash runway expected through 2028, sufficient for PBGENE-HBV and PBGENE-DMD data milestones

Financial Impact

Revenue of $10.8M (up from ~$0.1M YoY) driven by milestone payments; net loss improved to $(18.4M) from $(20.6M) YoY

revenuenet losscash position

Risk Factors

PBGENE-HBV Phase 1 data at EASL may show safety or efficacy concerns
PBGENE-DMD enrollment could face delays at specialized clinical sites
Reliance on milestone revenue from partners (TG Therapeutics, Imugene) is non-recurring
Operating loss of $(9.1M) in Q1 2026 still significant for a $197M market cap company

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001628280-26-030123
Document: dtil-20260505.htm	0001628280-26-030123
Document: 0001628280-26-030123-index-headers.html	0001628280-26-030123
Document: 0001628280-26-030123-index.html	0001628280-26-030123
Document: 0001628280-26-030123.txt	0001628280-26-030123
8-K Data (Synthetic)	0001628280-26-030123

5 reports for DTIL

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for DTIL — sortable, filterable
	Type				Now
May 27, 2026 18d ago	8-K BULLISH ★ 7/10	$7.59 $6.32	▼ −16.73%	▼ −17.94%	$6.10 (−19.63%)
May 26, 2026 19d ago	8-K NEUTRAL ★ 4/10	$7.59 $6.04	▼ −20.42%	▼ −20.89%	$6.10 (−19.63%)
May 5, 2026 5w ago	8-K NEUTRAL ★ 4/10	$7.45 $8.20	▲ +10.07%	▲ +8.08%	$6.10 (−18.12%)
Apr 8, 2026 9w ago	DEFA14A NEUTRAL ★ 3/10	$5.99 $7.66	▲ +27.88%	▲ +24.36%	$6.10 (+1.84%)
Mar 12, 2026 13w ago	8-K NEUTRAL ★ 4/10	$5.67 $6.72	▲ +18.52%	▲ +19.50%	$6.10 (+7.58%)

US Market Status

Market Closed — Opens in 5h 6m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access